The FDA approved Moderna’s Biologics License Application (BLA) for its mRNA-based flu vaccine, mRNA-1010 (mFlusiva; Moderna), ...

Health plans can use routine pharmacy claims to identify members at high risk for early discontinuation of glucagon-like peptide-1 receptor agonists and deliver targeted, equity-conscious adherence ...

Eligibility definitions differ across reports, particularly whether prior failure on highest approved antiobesity dose is required versus documenting discussion of all standard treatments. A one-off ...

Bruton tyrosine kinase (BTK) inhibitors have become a mainstay of treatment for relapsed or refractory (R/R) mantle cell ...

Steven D. Nathan, MD, discusses inhaled treprostinil and why inhaled therapies could mark the next frontier in idiopathic pulmonary fibrosis (IPF) care. “I think this further opens the door for other ...

Senate confirmation restores a durable leadership structure for CDC accountability after protracted reliance on interim arrangements and questions under the Federal Vacancies Reform Act. Contentious ...

Prior authorization, coverage limits, and affordability screening increasingly determine when CAR T or bispecifics are ...

Anosheh Afghahi, MD, discusses biomarker testing, trial matching technology, and community-academic partnerships to improve ...

Rising summer temperatures and prolonged UV exposure can accelerate the breakdown of larger plastics into these microscopic particles, increasing opportunities for human exposure, ...

UPMC and Birth Root Community Doula describe a 4-year partnership addressing food insecurity, housing, and maternal health ...

Six peptides received narrow advisory support for potential 503A Bulks List inclusion, an atypical outcome given FDA staff recommendations against all seven under review. Legal compounding remains ...

Young adults with sarcoma face challenges that extend well beyond treatment, and closing gaps in research funding and specialty care could improve outcomes for this population and beyond, according to ...